Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Cash: 2017-2025

Historic Change in Cash for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$146,000.

  • Aclaris Therapeutics' Change in Cash fell 100.59% to -$146,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.4 million, marking a year-over-year decrease of 360.07%. This contributed to the annual value of -$15.3 million for FY2024, which is 183.53% down from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Change in Cash is -$146,000, which was up 97.05% from -$5.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Change in Cash's 5-year high stood at $78.2 million during Q2 2021, with a 5-year trough of -$59.8 million in Q3 2021.
  • In the last 3 years, Aclaris Therapeutics' Change in Cash had a median value of -$555,000 in 2023 and averaged -$1.8 million.
  • In the last 5 years, Aclaris Therapeutics' Change in Cash surged by 465.24% in 2021 and then slumped by 2,854.30% in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Change in Cash stood at -$26.3 million in 2021, then surged by 37.62% to -$16.4 million in 2022, then surged by 105.12% to $838,000 in 2023, then plummeted by 2,854.30% to -$23.1 million in 2024, then plummeted by 100.59% to -$146,000 in 2025.
  • Its Change in Cash was -$146,000 in Q3 2025, compared to -$5.0 million in Q2 2025 and $5.8 million in Q1 2025.